Antisense therapy restores fragile X protein production in human cells
Science Daily: Pharmacology News
JULY 5, 2023
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.
189 
Sino Biological: new US centre for bioprocessing
Drug Target Review
OCTOBER 10, 2023
The company specialises in recombinant protein production and antibody development. All of Sino Biological’s products are independently developed and produced with a stringent quality management system, and include unique bioreagents addressing areas such as cell therapy, stem cell, and infectious disease research.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Series A Financing of 570 Million Yen Procured by Epsilon Molecular Engineering: A Next-Generation Medium Sized Molecular Biotechnology-Based Drug Discovery Firm
The Pharma Data
DECEMBER 22, 2020
Using the obtained sequencing data, Kao Corporation was able to produce an antibody sample in one week using protein production technology such as enzymes cultivated by our technology. Comment from Fumiharu Muroga, Growth Manager at Real Tech Fund] “Proteins are an important structural component of living things.
Targeting a human protein may stop Ebola virus in its tracks
The Pharma Data
MARCH 23, 2022
In fact, antiviral therapies designed to treat viruses such as hepatitis C (Sofosbuvir/SOVALDI) work by blocking viral polymerase. Without the stop sign, viral transcription no longer follows the correct order, which has a negative impact on viral protein production,” says Fang. The problems with Ebola polymerase.
A Look Back
Dark Matter Blog
JULY 16, 2021
At Biogen, my group’s work covered a range of technology development areas including protein production in mammalian cells, intracellular protein delivery (our work on HIV Tat started the field of cell-penetrating peptides) and novel gene delivery vehicles, as well as biological drug discovery and development. Failure is common.
Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input
Agency IQ
APRIL 12, 2024
Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue. How does “potency” apply to cell and gene therapy (CGT) products?
Gene editing extends lifespan in mouse model of prion disease
Broad Institute
JANUARY 14, 2025
His lab had just developed base editing, a gene-editing approach that makes single-letter changes in DNA and can shut down protein production using strategies including installing a stop signal in the genetic code. Theres still a long way to go to make this a therapy, Minikel said. Nature Medicine. Online January 14, 2025.
Let's personalize your content